
|Articles|February 9, 2016
AJMC's Dr Fendrick Testifies on Benefit of Clinical Nuance
Author(s)Laura Joszt, MA
A. Mark Fendrick, MD, co-editor-in-chief of The American Journal of Managed Care and director of the University of Michigan Center for Value-Based Insurance Design, testified before a Michigan senate subcommittee on the benefit of clinical nuance.
Advertisement
On Tuesday, The American Journal of Managed Care’s co-editor-in-chief, A. Mark Fendrick, MD, who is also the director of the
Advertisement
Related to this article

Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.

Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.

Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
4
Real-World Resmetirom Data Look Promising in MASH: Naim Alkhouri, MD
5

